Pharmaceutical compositions for minocycline

a technology of compositions and minocycline, which is applied in the field of compositions comprising minocycline, can solve the problems of reduced compliance rate of subjects, wide variations, and subjects experiencing vestibular adverse effects, and achieve the effect of predicting and accurate fractional doses of minocyclin

Pending Publication Date: 2021-11-18
DR REDDYS LAB LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new tablet of minocycline that does not contain lactose. The tablet has a score or separation mark that allows it to be divided into equal parts. This new tablet formulation reduces the number of specialized products, which makes it easier for pharmacies and warehouses to manage their inventory. The tablet comes in three strengths (55 mg, 82.5 mg, or 165 mg) and is a more efficient way to use this medication.

Problems solved by technology

Conventional dosage forms containing minocycline require frequent ingestion of multiple doses per day, resulting in wide variations in serum concentration throughout the course of treatment and some subjects experiencing vestibular adverse effects with immediate release oral dosage forms.
Such downsides relating to minocycline dosage forms ultimately lead to reduced rates of subject compliance.
SOLODYN® doesn't provide flexibility of dosing especially to subjects having swallowing disability such as dysphagia.
Additionally, it contains lactose which is highly reactive due to its hemiacetal structure and which can eventually cause chemical instability with active components.
Further, due to the solubility of minocycline of around 50 mg / ml, the drug has extremely poor binding affinity towards pharmaceutically acceptable excipients and hence, to provide a predictable and accurate fractional dose is difficult.
However, handling these many units (SKU) is cumbersome in manufacturing, supply chain, inventory and for chemists.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions for minocycline
  • Pharmaceutical compositions for minocycline
  • Pharmaceutical compositions for minocycline

Examples

Experimental program
Comparison scheme
Effect test

examples 1-3

[0320]The tablets of the present application comprising minocycline are prepared as described herein.

TABLE 1Quantity per unit (%)CompositionEx-1Ex - 2Ex - 3Ex - 4Drug loadingInert core14.861312.6613Minocycline Hydrochloride15.812.6713.4612.67(equivalent to Minocycline 135mg)Hydroxy propyl cellulose3.453.453.453.45Hydroxy propyl methyl cellulose1.801.851.851.85Polyethylene glycol 4000.520.690.670.69Talc0.791.821.771.82Water qs to 15.7% w / wqsqsqsqsTotal37.2233.5333.7133.53Barrier coatingHydroxy propyl methyl cellulose1.861.671.681.67Polyethylene glycol 4000.180.160.160.16Talc0.550.500.500.50WaterqsqsqsqsTotal2.592.342.352.34Extended release coatingEthyl cellulose5.434.693.934.69Hydroxy propyl methyl cellulose1.811.561.311.56Triethyl citrate0.540.460.390.46Talc2.171.871.571.87Isopropyl alcoholqsqsqsqsWaterqsqsqsqsTotal9.958.607.28.60Outer top coatingHydroxy propyl methyl cellulose5.343.803.863.80Polyethylene glycol 4000.530.380.380.38Talc1.601.131.161.13WaterqsqsqsqsTotal7.475.325.45.3...

example 5

[0331]The tablet comprising minocycline as prepared in example 4 was subjected to content uniformity studies as intact tablet and after dividing into two equal subunits. The results are shown in table 2.

TABLE 2IntactAssay % - Example 4No. of unitsIntact tabletDivision 1Division 2110199952991029539710193497103935961039369810193799999289899919999994109910292Mean98.510193Acceptance3.848.7Value% Relative1.511.661.44standarddeviationResultPassPassPass

example 6

[0332]The tablet comprising minocycline as prepared in example 2 was subjected to dissolution studies in 900 ml of pH 2.1 Simulated Gastric Fluid, pH 4.5 acetate buffer and pH 5.5 phosphate buffer with USP Type I apparatus at a speed of 100 rpm and 37° C. till 6 hours and the in-vitro release profile are shown in FIGS. 1, 2 and 3 respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.

Description

RELATED APPLICATIONS[0001]This application claims priority from U.S. patent application Ser. No. 15 / 093,673, filed Apr. 7, 2016 and Indian Provisional Application No. 1815 / CHE / 2015, filed Apr. 7, 2015.TECHNICAL FIELD[0002]The present invention relates to a composition comprising minocycline, a method of orally administering a once daily tablet of minocycline to a subject in need thereof, and a processes for preparing the tablet thereof.BACKGROUND[0003]Minocycline is a semi synthetic derivative of tetracycline, [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. The Orange Book of USFDA lists various dosage forms of minocycline hydrochloride such as immediate release (IR) tablets, capsules, and extended release (ER) tablets, indicated for the treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in subjects 12 years of age and older. Intravenous injection is availab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/65A61K9/20A61K9/00A61K9/28
CPCA61K31/65A61K9/2077A61K9/2886A61K9/2072A61K9/2866A61K9/0053A61P17/10A61P31/04
Inventor LOWALEKAR, ROHITPADHI, BIJAY KUMARRAGHUVANSHI, RAJEEV SINGH
Owner DR REDDYS LAB LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap